title: Effect of troglitazone on CYP1A1 induction.
abstract: Several peroxisome proliferators enhance CYP1A1 activity, but the mechanisms involved in this enhancement remain unknown. In this study, we examined the effect of troglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, on CYP1A1 gene expression and explored the mechanisms involved in these effects. Troglitazone increased gene expression of CYP1A1 mRNA and also increased CYP1A1-specific 7-ethoxyresorufin-O-deethylase (EROD) activity in a dose-dependent manner. Moreover, concomitant treatment with troglitazone and GW9662, a PPAR antagonist, markedly reduced the troglitazone-inducible EROD activity. Luciferase reporter assays using Hepa-1c1c7 cells showed a significant transactivation by troglitazone with a reporter plasmid containing a region from -1395 to +7 of the CYP1A1 gene. We found that a putative peroxisome proliferator-response element (PPRE) between -521 and -500 is located in the CYP1A1 gene promoter. Their inactivation by deletion mutagenesis suppressed the inductive effect of troglitazone on CYP1A1 promoter activation. Electrophoretic mobility shift assay revealed that troglitazone induced the activation of the PPAR-gamma to a form capable of binding specifically to the PPRE sequence of the CYP1A1 gene promoter. Furthermore, troglitazone increased the formation of the benzo[a]pyrene (BaP)-DNA adduct. Overall, our results suggest that troglitazone induces CYP1A1 enzyme activity and gene expression through PPAR-gamma activation, and may be involved in carcinogenesis.
authors.affiliation: BK21 Project Team, Department of Pharmacy, College of Pharmacy, Research Center for Proteineous Materials, Chosun University, 375 Seosuk-dong, Gwangju 501-759, South Korea.
authors.forename: Hyung Gyun
authors.initials: HG
authors.lastname: Kim
authors.forename: Eun Hee
authors.initials: EH
authors.lastname: Han
authors.forename: Hye Gwang
authors.initials: HG
authors.lastname: Jeong
mesh_terms: D000813:Anilides / Q000494:pharmacology; D000818:Animals; D001564:Benzo(a)pyrene / Q000737:chemistry; D045744:Cell Line, Tumor; D002839:Chromans / Q000737:chemistry / Q000494:pharmacology*; D019363:Cytochrome P-450 CYP1A1 / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D018736:DNA Adducts / Q000096:biosynthesis / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004790:Enzyme Induction; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D047495:PPAR gamma / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D045162:Thiazolidinediones / Q000737:chemistry / Q000494:pharmacology*; D000077288:Troglitazone
chemical_list: C457499:2-chloro-5-nitrobenzanilide; D000813:Anilides; D002839:Chromans; D018736:DNA Adducts; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D012333:RNA, Messenger; D045162:Thiazolidinediones; D001564:Benzo(a)pyrene; D019363:Cytochrome P-450 CYP1A1; D000077288:Troglitazone